These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 21272954)

  • 1. Lung cancer in never smokers: change of a mindset in the molecular era.
    Lee YJ; Kim JH; Kim SK; Ha SJ; Mok TS; Mitsudomi T; Cho BC
    Lung Cancer; 2011 Apr; 72(1):9-15. PubMed ID: 21272954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lung cancer in never smokers: a review.
    Subramanian J; Govindan R
    J Clin Oncol; 2007 Feb; 25(5):561-70. PubMed ID: 17290066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal growth factor receptor abnormalities in lung cancer. Pathogenetic and clinical implications.
    Prudkin L; Wistuba II
    Ann Diagn Pathol; 2006 Oct; 10(5):306-15. PubMed ID: 16979526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors.
    Bonomi PD; Buckingham L; Coon J
    Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4606-12. PubMed ID: 17671150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lung cancer in never smokers.
    Torok S; Hegedus B; Laszlo V; Hoda MA; Ghanim B; Berger W; Klepetko W; Dome B; Ostoros G
    Future Oncol; 2011 Oct; 7(10):1195-211. PubMed ID: 21992731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of environmental tobacco smoke on the incidence of mutations in epidermal growth factor receptor gene in never-smoker patients with non-small-cell lung cancer.
    Lee YJ; Cho BC; Jee SH; Moon JW; Kim SK; Chang J; Chung KY; Park IK; Choi SH; Kim JH
    J Clin Oncol; 2010 Jan; 28(3):487-92. PubMed ID: 20008630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding the new genetics of responsiveness to epidermal growth factor receptor tyrosine kinase inhibitors.
    Toschi L; Cappuzzo F
    Oncologist; 2007 Feb; 12(2):211-20. PubMed ID: 17296817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.
    John T; Liu G; Tsao MS
    Oncogene; 2009 Aug; 28 Suppl 1():S14-23. PubMed ID: 19680292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lung cancer mutation profile of EGFR, ALK, and KRAS: Meta-analysis and comparison of never and ever smokers.
    Chapman AM; Sun KY; Ruestow P; Cowan DM; Madl AK
    Lung Cancer; 2016 Dec; 102():122-134. PubMed ID: 27987580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor mutations in small cell lung cancer.
    Tatematsu A; Shimizu J; Murakami Y; Horio Y; Nakamura S; Hida T; Mitsudomi T; Yatabe Y
    Clin Cancer Res; 2008 Oct; 14(19):6092-6. PubMed ID: 18829487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
    Jänne PA; Johnson BE
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-line treatment for advanced nonsmall cell lung cancer harboring activating epidermal growth factor receptor mutation: epidermal growth factor receptor tyrosine kinase inhibitors or chemotherapy?
    Gridelli C
    Curr Opin Oncol; 2011 Mar; 23(2):131-2. PubMed ID: 21307676
    [No Abstract]   [Full Text] [Related]  

  • 13. Dominance of EGFR and insignificant KRAS mutations in prediction of tyrosine-kinase therapy for NSCLC patients stratified by tumor subtype and smoking status.
    Pesek M; Benesova L; Belsanova B; Mukensnabl P; Bruha F; Minarik M
    Anticancer Res; 2009 Jul; 29(7):2767-73. PubMed ID: 19596959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history.
    Mounawar M; Mukeria A; Le Calvez F; Hung RJ; Renard H; Cortot A; Bollart C; Zaridze D; Brennan P; Boffetta P; Brambilla E; Hainaut P
    Cancer Res; 2007 Jun; 67(12):5667-72. PubMed ID: 17575133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary and secondary therapeutic strategies for EGF receptor pathway inhibition in non-small-cell lung cancer.
    Batus M; Fidler MJ; Bonomi PD
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1589-99. PubMed ID: 20942630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal growth factor receptor mutations detected by denaturing high-performance liquid chromatography in nonsmall cell lung cancer: impact on response to therapy with epidermal growth factor receptor-tyrosine kinase inhibitors.
    Cohen V; Agulnik JS; Ang C; Kasymjanova G; Batist G; Small D; Brandao G; Chong G; Miller WH
    Cancer; 2010 Sep; 116(18):4309-17. PubMed ID: 20549828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Personalized medicine for non-small-cell lung cancer.
    Mok TS; Zhou Q; Leung L; Loong HH
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1601-11. PubMed ID: 20942631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors.
    Calvo E; Baselga J
    J Clin Oncol; 2006 May; 24(14):2158-63. PubMed ID: 16682734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lung cancer in 'Never-smokers': a unique entity.
    Subramanian J; Govindan R
    Oncology (Williston Park); 2010 Jan; 24(1):29-35. PubMed ID: 20187318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular genetics of lung cancer in people who have never smoked.
    Subramanian J; Govindan R
    Lancet Oncol; 2008 Jul; 9(7):676-82. PubMed ID: 18598932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.